Skip to content
Search

Latest Stories

Submit Guest Post

Top Morrisons investor says CD&R should raise takeover bid

ONE of Morrisons top shareholder, J O Hambro said that US private equity firm Clayton, Dubilier & Rice (CD&R) must raise the bid amount for takeover to succeed.

The UK-based asset management company said that any potential bidder for the supermarket group should raise its offer to £6.5 billion.


Last week, Morrisons declined a £5.5bn takeover proposal from the CD&R, saying the offer “significantly undervalues” the firm.

J O Hambro, which owns 3 per cent of Morrisons, said this was a “high-octane” approach that would “create a more volatile asset”.

J O Hambro backed the Morrisons decision to decline the £5.5 bn takeover offer and said that CD&R should pay a “fair price” to merge the supermarket’s petrol station arm with its Motor Fuels Group – a combined company that would create a forecourt giant with around 1200 sites across the UK.

“The fuel purchasing and food retailing synergies here are clear to see,” the shareholder said. “But CD&R should pay a fair price in order to access those synergies.”

Morrisons is Britain’s fourth largest grocer by sales after Tesco, Sainsbury’s and Asda.

Meanwhile, British takeover rules give CD&R until July 17 to come back with a higher offer.

Amazon, and private equity firms Apollo, Lone Star and KKR, are all understood to be interested in a potential takeover of the supermarket.

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

AstraZeneca

AstraZeneca chief executive Pascal Soriot says the company has the science, pipeline and team to deliver its long-term growth ambitions

Getty Images

AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment

  • AstraZeneca expects its restructuring programme to generate $1.5bn in annualised savings by 2029, with most of the money reinvested in research and development.
  • The plan could incur up to $2bn in one-off restructuring costs, although the company expects its overall workforce to continue growing.
  • Third-quarter revenue rose 7 per cent to $16.21bn, while oncology sales increased 17 per cent to $7.77bn.

AstraZeneca has unveiled plans to generate around $1.5bn in annual savings through a three-year restructuring programme, as chief executive Pascal Soriot shifts the focus back to growth and investment in its drug pipeline.

The British-based pharmaceutical group said its Reshaping for Sustainable Growth programme would redirect resources towards research and development, particularly its pipeline of more than 180 projects and emerging technologies.

Keep ReadingShow less